Intelligence Report · ~12 min read

Pfizer Intelligence Report

Generated from 134 signals · 13 evidence sources

Type

Company Intelligence Report

Generated

Jul 22, 2026

Confidence

Moderate Confidence · 68%

Evidence

724 items

Sources

216

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Pfizer maintains an active intelligence profile across Oncology, mTOR Inhibitor, Lung Cancer, Diabetes, GLP-1. 134 signals are linked with 12 investigate-priority items requiring leadership attention. Competitive pressure is moderate with high portfolio impact. Evidence coverage stands at 68% across 13 tracked sources. Highest-priority development: FDA Approves PHESGO Supplement for Genentech's Combination Therapy. Portfolio development. FDA Approves PHESGO Supplement for Genentech's Combination Therapy is an owned Pfizer portfolio development in Oncology · HER2-positive Breast Cancer.

Key Developments

Material intelligence events ranked by strategic relevance.

investigateJun 17, 2026
Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients
Oncology · Multiple Myeloma · opportunity score 456
View detail
investigateJun 16, 2026
Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Oncology · NSCLC · opportunity score 456
View detail
investigateJun 16, 2026
Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Infectious Disease · Pneumococcal Vaccine · opportunity score 456
View detail
investigateJul 2, 2026
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Oncology · KRAS G12C Non-Small Cell Lung Cancer · opportunity score 454
View detail
investigateJul 2, 2026
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Oncology · KRAS G12C NSCLC · opportunity score 453
View detail
investigateJun 20, 2026
RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization
Oncology · Multiple Myeloma · opportunity score 453
View detail
investigateJun 16, 2026
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Oncology · NSCLC · opportunity score 453
View detail
investigateJul 11, 2026
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Oncology · Bladder Cancer · opportunity score 452
View detail
investigateJun 27, 2026
Lilly's Jaypirca recommended for EU approval in CLL across all therapy lines
Hematology · CLL · opportunity score 451
View detail
investigateJun 10, 2026
FDA Approves Pfizer’s HYMPAVZI for Expanded Hemophilia A and B Indications
Hematology · Hemophilia A/B · opportunity score 451
View detail
investigateJun 30, 2026
FDA Drug Trials Snapshot: YARTEMLEA Approved for TA-TMA
Hematology · Thrombotic Microangiopathy · opportunity score 449
View detail
investigateJun 16, 2026
Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV · opportunity score 449
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 60289 with buyer quality 10 (Enterprise). Competitive pressure: Moderate. Portfolio impact: High. 12 investigate-priority signals warrant near-term portfolio review. Competitiva linkage surfaces 8 competitive findings requiring monitoring.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
High Confidence · 95%
Potential competitive pressure
Source: Pfizer, Competitiva
View evidence
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
High Confidence · 95%
Potential competitive pressure
Source: Pfizer, Competitiva
View evidence
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Moderate Confidence · 67%
Potential competitive pressure
Source: Pfizer, Competitiva
View evidence
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
High Confidence · 95%
Potential competitive pressure
Source: Pfizer, Competitiva
View evidence
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
High Confidence · 95%
Potential competitive pressure
Source: Humanexa Signals, Competitiva
View evidence
Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development
High Confidence · 95%
Potential competitive pressure
Source: PubMed, Competitiva
View evidence
Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development
High Confidence · 95%
Potential competitive pressure
Source: Pfizer, Competitiva
View evidence
Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development
High Confidence · 95%
Potential competitive pressure
Source: Humanexa Signals, Competitiva
View evidence
FDA Approves PHESGO Supplement for Genentech's Combination Therapy
Low Confidence · 0%
FDA approval
Source: Pfizer, FDA, Portfolio
View evidence
FDA Grants Priority Review for KISQALI Supplement by Novartis
Low Confidence · 0%
FDA approval
Source: FDA, FDA, Portfolio
View evidence
FDA Accepts Supplement for OLUMIANT (Baricitinib) by Eli Lilly
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, FDA, Portfolio
View evidence
FDA Accepts Supplement for OLUMIANT (Baricitinib) by Eli Lilly
Low Confidence · 0%
FDA approval
Source: Pfizer, FDA, Portfolio
View evidence
FDA Approves Pembrolizumab Combinations for Muscle Invasive Bladder Cancer
Low Confidence · 0%
FDA approval
Source: Pfizer, FDA, Portfolio
View evidence
FDA Accepts Supplemental Application for Emgality (Galcanezumab)
Low Confidence · 0%
FDA approval
Source: FDA, FDA, Portfolio
View evidence
FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis
Low Confidence · 0%
FDA approval
Source: Pfizer, FDA, Portfolio
View evidence
FDA Acceptance of Supplemental NDA for REVLIMID by Bristol Myers Squibb
Low Confidence · 0%
FDA approval
Source: Pfizer, FDA, Portfolio
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

FDA Approves Supplemental Application for IBRANCE (Palbociclib)
Oncology · CDK4/6 Inhibitor
Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna
Oncology · Non-small Cell Lung Cancer
FDA approves capivasertib with abiraterone for PTEN-deficient prostate cancer
Oncology · Prostate Cancer
Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients
Oncology · Multiple Myeloma
Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Oncology · NSCLC
Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Infectious Disease · Pneumococcal Vaccine
AstraZeneca licenses novel EGFR inhibitor Zegfrovy for lung cancer
Oncology · EGFR Inhibitor
FDA Approves Palbociclib with Trastuzumab for HR-positive, HER2-positive Breast Cancer
Oncology · Breast Cancer

Executive Summary

Key Developments

Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC

Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment

Lilly's Jaypirca recommended for EU approval in CLL across all therapy lines

FDA Approves Pfizer’s HYMPAVZI for Expanded Hemophilia A and B Indications

FDA Drug Trials Snapshot: YARTEMLEA Approved for TA-TMA

Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir

Strategic Implications

Supporting Evidence

European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development

Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development

Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development

FDA Approves PHESGO Supplement for Genentech's Combination Therapy

FDA Grants Priority Review for KISQALI Supplement by Novartis

FDA Accepts Supplement for OLUMIANT (Baricitinib) by Eli Lilly

FDA Accepts Supplement for OLUMIANT (Baricitinib) by Eli Lilly

FDA Approves Pembrolizumab Combinations for Muscle Invasive Bladder Cancer

FDA Accepts Supplemental Application for Emgality (Galcanezumab)

FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis

FDA Acceptance of Supplemental NDA for REVLIMID by Bristol Myers Squibb

Related Intelligence

Signals